Cruz-Guillén AA, Cortés-Espinosa T, Sánchez-Chávez X, López GJG, GQuintero AG, Reyes ZMG, Ramos GMV

Language: Spanish
References: 14
Page: 224-230
PDF size: 826.46 Kb.

ABSTRACT

Background: Previous studies done in patients affected with inflammatory bowel disease (IBD) have suggested the presence of genetic and environmental factors influencing the clinical behavior of this disease.
AIM: This work intended to evaluate, descriptively and retrospectively, the clinical behavior and treatments on a group of Mexican patients affected by IBD and compare our results with results published in similar studies carried out in mexico-american patients, analyzed in other countries and determine differences between results.
Materials and methods: We did a descriptive and retrospective analysis in 85 patients diagnosed as Nonspecific Ulcerative Colitis and Chron’s Disease. We analyzed: Method of diagnosis, extension of disease, medical and/or surgical treatment and mortality. We obtained results from Mexican population and compared them with results obtained from Mexico-american population published elsewhere.
Results: We obtained a population of 85 patients, 57.6% female and 42.3% male. Most of them were affected by ulcerative colitis. We found only familial history of disease in 2 cases. In relationship to extension of disease, we found a higher prevalence of left-sided colitis in Mexican patients than in mexico-american population; however, the frequency of proctitis in both groups was similar. Related to medical treatment, we found that Mexican population was treated in a higher frequency with biological therapeutic agents than mexico-american patients. Related to surgical treatment, we did not find statistical differences between groups.
Conclusions: Our study, which describes the principal characteristics and clinical behavior of IBD in Mexican population, shows that similar genetic and cultural population, in different environmental conditions, show slight differences, related principally left-sided colitis, higher mortality, and higher usage of biological agents. Our results support the role of environment on clinical characteristics of IBD.

REFERENCES

1. Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol 2008;8:458-466.

2. Loftus EV, Sandborn WJ. Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am 2002;31:1-20.

3. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-434.

4. Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol 2008;14:354-377.

5. Nguyen GC, et al. Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am J Gastroenterol 2006;101:1012-1023.

6. Basu D, Lopez I, Kulkarni A, Sellin JH. Impact of race and ethnicity on inflammatory bowel disease. Am J Gastroenterol 2005;100:2254-2261.

7. Silva-Zolezzi I, et al. Analysis of genomic diversity in Mexican Mestizo populations to develop genomic medicine in Mexico. Proc Natl Acad Sci 2009;106:8611-8616.

8. Brant SR, Nguyen GC. Is there a gender difference in the prevalence of Crohn’s disease or ulcerative colitis? Inflamm Bowel Dis 2008;14 Suppl 2: S2-3.

9. Simsek H, Schuman BM. Inflammatory bowel disease in 64 black patients: analysis of course, complications, and surgery. J Clin Gastroenterol 1989;11:294-298.

10. Tang H, et al. Genetic structure, self-identified race/ethnicity, and confounding in case-control association studies. Am J Hum Genet 2005;76:268-275.

11. Rutgeerts P, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-2476.

12. Hanauer SB, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002;359:1541-1549.

13. Yamamoto-Furusho JK, Bosques-Padilla F. Mexican consensus on the use of agents anti-TNF-alpha in the treatment of inflammatory bowel disease. Rev Gastroenterol Mex 2009;74:263-278.

14. Lawrance IC, Murray K, Hall A, Sung JJ, Leong R. A prospective comparative study of ASCA and pANCA in Chinese and Caucasian IBD patients. Am J Gastroenterol 2004;99:2186-2194.